PFIZER/ALZA EXTENDED-RELEASE GLIPIZIDE (GLUCOTROL XL) MARKETING
PFIZER/ALZA EXTENDED-RELEASE GLIPIZIDE (GLUCOTROL XL) MARKETING will begin "immediately" through Pfizer's Pratt Pharmaceuticals Division. Pfizer announced the approval of the anti-diabetes product on April 28 at its annum meeting, two days after FDA clearance and less than two weeks prior to the expiration of Pfizer's exclusive marketing protection for the standard-release dosage form of glipizide (Glucotrol). Worldwide sales of Glucotrol were $63.5 mil. (up 18%) in 1993.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth